2. Search Result
Search Result
Results for "

HLA-G

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

1

Peptides

9

Inhibitory Antibodies

13

Recombinant Proteins

2

Antibodies

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-RS06217
    HLA-G Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    HLA-G Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-G gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    HLA-G Human Pre-designed siRNA Set A
    HLA-G Human Pre-designed siRNA Set A
  • HY-P990714
    Obertamig

    		CD3 Inflammation/Immunology
    Obertamig is an engineered, humanized, anti-CD3E/HLA-G monoclonal antibody with humanized CH2-CH3 modifications and consists of half immunoglobulin IgG1 λ2 and a single-chain variable fragment (scFv) .
    Obertamig
  • HY-P990061
    Polzastobart

    JTX 8064

    		 LILRB Transmembrane Glycoprotein Inflammation/Immunology Cancer
    Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor .
    Polzastobart
  • HY-P11340
    VMAPRTLFL

    		MHC Infection Inflammation/Immunology
    VMAPRTLFL is a 9-mer peptide derived from the signal peptide of HLA-G and can serve as a peptide ligand for HLA-E. VMAPRTLFL plays a crucial role in regulating the functions of adaptive natural killer (NK) cells. Specifically, VMAPRTLFL enriches FcεRγ - adaptive NK cells, upregulates the expression of CD25, and enhances their proliferative activity, antibody-dependent cellular cytotoxicity (ADCC), and IFN-γ release. VMAPRTLFL can be used in research related to human cytomegalovirus (HCMV) infection, transplant rejection, and pregnancy immunity .
    VMAPRTLFL
  • HY-P992018
    Anti-HLA-G Antibody

    		MHC Inflammation/Immunology
    Anti-HLA-G Antibody is an anti-HLA-G antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-HLA-G Antibody
  • HY-P992111
    Elfritatug

    UCB4594

    		 MHC Cancer
    Elfritatug (UCB4594) is a humanized monoclonal antibody targeting human leukocyte antigen-G (HLA-G). By binding to HLA-G on the surface of tumor cells, Elfritatug blocks its immunosuppressive effect, thereby enhancing the body's immune response against tumors .
    Elfritatug
  • HY-169404
    PPARγ agonist 15

    		PPAR Metabolic Disease
    PPARγ agonist 15 (Compound 7c) is an agonist for PPARγ. PPARγ agonist 15 inhibits the expression of alpha-amylase (HPA) and alpha-glucosidase (HLAG) with IC50 of 28.35 µM and 26.21 µM. PPARγ agonist 15 enhances glucose uptake in the L6 myotube cell. PPARγ agonist 15 improves glucose homeostasis, insulin sensitivity, and lipid metabolism in rat Streptozotocin (HY-13753)-induced diabetes model .
    PPARγ agonist 15
  • HY-P992388
    IO-108

    		LILRB Cancer
    IO-108 is a humanized IgG4 monoclonal antibody and a competitive inhibitor of LILRB2, with a KD value of 1.97 nM. IO-108 competitively blocks the binding of LILRB2 to its ligands including HLA-G, MHC-I, ANGPTL2 and SEMA4A, reprograms tumor-associated myeloid cells, drives the conversion of suppressive myeloid cells into a pro-inflammatory phenotype, and restores the cytotoxic activity of T cells and NK cells. IO-108 inhibits tumor growth in LILRB2 transgenic mouse models. IO-108 can be used for the research of solid tumors .
    IO-108
  • HY-P992254
    Anti-LAG-3 Antibody (BAP050)

    		LAG-3 Cancer
    Anti-LAG-3 Antibody (BAP050) is an anti-LAG3 antibody with Kd values of 9.0 nM (Equilibrium) and 0.80 nM (Kinetic) against hLAG3. Anti-LAG-3 Antibody (BAP050) binds to an epitope outside the 30-amino-acid residue loop in the first immunoglobulin-like domain (D1) of hLAG3. Anti-LAG-3 Antibody (BAP050) is applicable for cancer-related research. The isotype control is Mouse IgG1 kappa, Isotype Control (HY-P99977) .
    Anti-LAG-3 Antibody (BAP050)
  • HY-P992353
    ES009

    		LILRB Cancer
    ES009 is a high-affinity LILRB2 antagonist, with IC50 values of 14.07 nM and 18.61 nM for inhibiting hLILRB2-huANGPTL3 and hLILRB2-huANGPTL4, respectively. ES009 specifically blocks the interactions between LILRB2 and MHC class I as well as non-MHC ligands, thereby effectively inhibiting receptor activation. ES009 can reprogram anti-inflammatory myeloid cells and induce their conversion to a pro-inflammatory phenotype, and also reverse the T cell suppression mediated by macrophages. When combined with anti-PD-1 blockade therapy, ES009 synergistically enhances T cell activation. ES009 can be used in research related to advanced solid tumors and ovarian cancer .
    ES009

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: